Therapeutic Asset Ratings

831 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Meta-Iodobenzylguanidine Dementia	Mayo Clinic	P4	B (62)
Naltrexone Bipolar I Disorder	Mayo Clinic	P4	B (62)
Naltrexone Bipolar II Disorder	Mayo Clinic	P4	B (62)
Phentermine Bipolar I Disorder	Mayo Clinic	P4	B (62)
Phentermine Bipolar II Disorder	Mayo Clinic	P4	B (62)
Semaglutide Bipolar I Disorder	Mayo Clinic	P4	B (62)
Semaglutide Bipolar II Disorder	Mayo Clinic	P4	B (62)
Suvorexant Advanced Malignant Solid Neoplasm	Mayo Clinic	P4	B (62)
Suvorexant Hematopoietic And Lymphoid System Neoplasm	Mayo Clinic	P4	B (62)
Topamax Bipolar I Disorder	Mayo Clinic	P4	B (62)
Topamax Bipolar II Disorder	Mayo Clinic	P4	B (62)
Wellbutrin Bipolar II Disorder	Mayo Clinic	P4	B (62)
Wellbutrin Weight Loss	Mayo Clinic	P4	B (62)
Apalutamide Castration-Resistant Prostate Carcinoma	Mayo Clinic	P3	B (62)
CARVEDILOL Breast Carcinoma	Mayo Clinic	P3	B (62)
Epirubicin High Grade B-Cell Lymphoma, Not Otherwise Specified	Mayo Clinic	P3	B (62)
ETOPOSIDE Chronic Myelomonocytic Leukemia	Mayo Clinic	P3	B (62)
VIPIVOTIDE TETRAXETAN Metastatic Prostate Carcinoma	Mayo Clinic	P3	B (62)
Epirubicin Follicular Lymphoma	Mayo Clinic	P2	B (62)
FLUTICASONE Metastatic Melanoma	Mayo Clinic	P2	B (62)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Fallopian Tube Clear Cell Adenocarcinoma	Mayo Clinic	P2	B (62)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Fallopian Tube Carcinoma	Mayo Clinic	P2	B (62)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Ovarian Carcinoma	Mayo Clinic	P2	B (62)
Pembrolizumab Follicular Lymphoma	Mayo Clinic	P2	B (62)
Doxycycline Autoimmune Disease	Mayo Clinic	P4	B (61)

Showing 151 to 175 of 831 assets

PreviousPage 7 of 34Next